TABLE 1.
Fold increase in luciferase activity due to the presence of oriP sequences in EBNA1-positive or -negative cellsa
| Cell type | EBNA1 status | Fold increase in luciferase activity (oriP+/oriP−) |
|---|---|---|
| 293 | Negative | 0.6 |
| 293-EBNA1 | Positive | 100 |
| BJAB- K88 | Negative | 3 |
| BJAB- HR1K | Positive | 79 |
| BJAB- 95-8 | Positive | 126 |
| Daudi | Positive | 72 |
| NL03 | Negative | 1 |
| NL03/EBV | Positive | 61 |
The cell lines 293 and 293-EBNA1 were transfected with pTG11056 (oriP+) or pTG11077 (oriP−) as described in the legend to Fig. 1. In addition, the B- lymphoma cell lines BJAB- K88 (17), BJAB- HR1K (10), and BJAB- B95-8 (10), as well as Daudi cells (ATCC CCL-213), normal human lymphocytes (NL03), and an EBV-immortalized B-lymphoma cell line derived from NL03 (NL03/ EBV) were tested: 106 cells were transfected with 1 μg of pTG11056 (oriP+) or pTG11077 (oriP−) by using lipofectin. The cells were lysed 16 h after transfection, and the luciferase activity in one-fifth of the cell extract was quantified as described in the legend to Fig. 1.